Share on LinkedInShare on LinkedIn

ARTICLE · 23 MARCH 2022

The FTC Remains Focused On Misleading COVID-19 Claims

In 2020, the Federal Trade Commission ("FTC") sent letters to a number of direct sellers, alleging that they or members of their sales force had made false or misleading health and earnings claims related to COVID-19.

United StatesConsumer Protection

In 2020, the Federal Trade Commission (“FTC”) sent letters to a number of direct sellers, alleging that they or members of their sales force had made false or misleading health and earnings claims related to COVID-19. Then in 2021, Congress enacted the COVID-19 Consumer Protection Act (the “Act”), providing for civil penalties of up to $46,517 for every misleading claim about the treatment, cure, prevention, or mitigation of COVID-19. And just recently, many of our direct selling clients received letters from the FTC reminding them of the FTC's authority under the Act.

Although these “reminder” letters do not seek actual penalties, they demonstrate the FTC is actively monitoring the direct sales channel and searching for the right opportunity to strike. In fact, since the enactment of the Act, the FTC has taken an aggressive stance in targeting those companies and their distributors who attempt to capitalize on COVID-19 and its effects. The FTC is sending a clear

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from